The use of the immunosuppressants has revolutionized organ transplantation, including
pediatric heart transplantation (PHTx). Recent evidence has shown that pharmacogenomics …

In the transplantation field, genetic changes in a single nucleotide in the genes responsible
for the transport and metabolism of an immunosuppressive drug may modify the response of …

Tacrolimus has a narrow therapeutic window and a wide interindividual variation in its
pharmacokinetics. The cytochrome P450 3A (C YP3A) and the ATP-binding cassette B1 …

Individualization of immunosuppressive therapy after solid organ transplantation is a goal
that has been pursued for a long time. Nevertheless, in clinical practice, we are still …

With advances in immunosuppressive therapy, there have been significant improvements in
acute rejection rates and short‐term allograft survival in kidney transplant recipients …

Renal transplant outcomes exhibit large inter‐individual variability, possibly on account of
genetic variation in immune‐response mediators and genes influencing the …

Pharmacogenetics explains part of the interindividual variability in drug responses. Many
published works about the effects of single nucleotide polymorphisms (SNPs) on …

Advances in immunosuppressive therapy allowed renal transplantation to become the
treatment of choice for suitable candidates with (end stage renal disease) ESRD. The post …

Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The domain of solid organ transplantation is characterized by the use of variable drug
combinations with drug-drug interactions, and the presence of two genomes, that of the …